CEO of BioMarin Pharmaceutical Inc. (BMRN) Jean Jacques Bienaime buys 1,500 shares of BMRN on 06/12/2009 at an average price of $14.52 a share.
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating life-threatening chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product BM101 for the treatment of mucopolysaccharidosis-I or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans. BioMarin Pharmaceutical Inc. has a market cap of $1.5 billion; its shares were traded at around $15 with a P/E ratio of 93.8 and P/S ratio of 5.1.
No comments:
Post a Comment